Insider Selling: KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Sells $80,500.00 in Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 10,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $8.05, for a total transaction of $80,500.00. Following the completion of the sale, the insider now owns 2,876,027 shares in the company, valued at approximately $23,152,017.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Wednesday, September 13th, Holdings A/S Novo sold 25,900 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.02, for a total transaction of $207,718.00.
- On Friday, September 15th, Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $7.21, for a total transaction of $1,273,624.87.
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) opened at 6.96 on Monday. The stock’s market cap is $67.60 million. The firm has a 50-day moving average of $8.20 and a 200-day moving average of $7.83. KalVista Pharmaceuticals, Inc. has a one year low of $5.48 and a one year high of $10.65.
KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative net margin of 4,191.47% and a negative return on equity of 60.42%. The business had revenue of $0.10 million during the quarter. On average, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post ($2.94) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Insider Selling: KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Sells $80,500.00 in Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/18/insider-selling-kalvista-pharmaceuticals-inc-kalv-major-shareholder-sells-80500-00-in-stock.html.
A number of brokerages have weighed in on KALV. ValuEngine upgraded shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd. BTIG Research began coverage on shares of KalVista Pharmaceuticals in a report on Thursday, August 31st. They issued a “buy” rating and a $18.00 price objective on the stock.
A hedge fund recently bought a new stake in KalVista Pharmaceuticals stock. Eventide Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned approximately 1.01% of KalVista Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 75.66% of the company’s stock.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Stock Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.